Sergliflozin
Detailed article on Sergliflozin
| Drug Information | |||
|---|---|---|---|
| Image | 200 | ||
| Identifiers
ATC Code DrugBank UNII ChEBI
|
Chemical Data
Molecular Weight | ||
Sergliflozin is a pharmaceutical compound that belongs to the class of drugs known as SGLT2 inhibitors. These drugs are primarily used in the management of type 2 diabetes mellitus by promoting the excretion of glucose through the urine, thereby lowering blood glucose levels.
Mechanism of Action[edit | edit source]
Sergliflozin works by inhibiting the sodium-glucose co-transporter 2 (SGLT2) in the proximal tubules of the kidney. SGLT2 is responsible for the reabsorption of glucose from the glomerular filtrate back into the bloodstream. By inhibiting this transporter, sergliflozin reduces glucose reabsorption, leading to increased urinary glucose excretion and a reduction in blood glucose levels.
Pharmacokinetics[edit | edit source]
Sergliflozin is administered orally and is absorbed in the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily via the urine. The pharmacokinetic profile of sergliflozin includes a half-life that supports once-daily dosing, making it convenient for patients.
Clinical Use[edit | edit source]
Sergliflozin is indicated for the treatment of type 2 diabetes mellitus, particularly in patients who require additional glycemic control beyond what is achieved with diet, exercise, and other antidiabetic medications. It is often used in combination with other antidiabetic agents such as metformin or sulfonylureas.
Adverse Effects[edit | edit source]
Common adverse effects of sergliflozin include urinary tract infections, increased urination, and genital mycotic infections. These are related to the increased glucose concentration in the urine. Rare but serious side effects include ketoacidosis and acute kidney injury.
Contraindications[edit | edit source]
Sergliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or those on dialysis. It should also be used with caution in patients with a history of recurrent urinary tract infections or genital infections.
Research and Development[edit | edit source]
Sergliflozin is part of ongoing research to explore its potential benefits beyond glucose control, such as cardiovascular protection and weight loss. Studies are also investigating its effects on renal outcomes in patients with chronic kidney disease.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
